Keywords: ph, iii, mozobil, trial, meets, primary, endpoint

Ph III Mozobil trial meets primary endpoint

Article | 30 July 2007

Print This

US biotechnology firm Genzyme says that a Phase III trial of its oncology agent Mozobil (plerixafor) in non-Hodgkin's lymphoma has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in